Actualités

They are way more than just GLP-1 stocks.

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

Amgen is back in focus after updated valuation work lifted its modeled fair value from US$352.23 to US$371.93 per share, signaling a higher price target in the latest analyst run. Much of Wall Street commentary around this shift ties to recent Q2 beats, raised guidance, and differing views on how durable the current growth and pipeline story really is. As you read on, you will see how these moving pieces shape the evolving Amgen narrative and what to watch next in the research. Stay updated...

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

Rapid growth across cardiovascular, bone and rare-disease medicines allowed Amgen to raise guidance despite abandoning an obesity candidate.

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

The S&P 500 Index ($SPX ) (SPY ) today is up +0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures (ESU26 ) are up +0.50%, and September E-mini Nasdaq futures...

Stock Market Today: The Dow Jones index rises Wednesday after surprise jobs data. AMD stock and SpaceX plunge on earnings.

8.30am: ADP jobs softens US private-sector hiring slowed to 44,000 jobs in July from 98,000 in June, missing the 65,000 forecast and pointing to cooling labour demand. The softer reading could give the Federal Reserve more scope to cut rates, weighing on Treasury yields and the dollar...

Amgen Inc (AMGN) delivers 10% revenue growth driven by key products like Repatha and UPLIZNA, while raising full-year 2026 guidance.

By Deena Beasley Aug 3 (Reuters) - Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the

US equities rallied intraday, fueled by upbeat earnings reports and hopes that the Strait of Hormuz

Stock Market Today: The Dow Jones index rallied 600 points Monday after Trump called off new U.S. strikes on Iran. Oil prices plunged.

Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.

Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer.

Amgen (NasdaqGS:AMGN) received a positive opinion from the European Medicines Agency’s CHMP for an expanded Repatha indication in Europe. The recommendation covers use of Repatha to help reduce cardiovascular risk in high risk adults without a prior heart attack or stroke. The CHMP view is based on Phase 3 clinical data that showed a significant reduction in major adverse cardiovascular events. Amgen is a large biotech company with a focus on cardiometabolic, oncology and immunology...

Getting kicked off the Dow Jones Industrial Average sounds like a death sentence for a stock, but a handful of booted dividend giants went on to reward patient shareholders with stunning gains and steady income streams that index investors missed out on entirely.

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Merck snagged the first-ever approval for a PCSK9 pill to lower LDL cholesterol, starting a new rivalry with injection-makers.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing investors to ask if the price of admission is simply too high.

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.

Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.

Jefferies initiated coverage of Quantinuum stock with a buy rating, touting the company's broad hardware and software platform.

The deal adds navtemadlin—a drug candidate for a rare blood cancer in late-stage clinical trials—to Ipsen’s oncology pipeline.

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.

While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.